scispace - formally typeset
Search or ask a question
Topic

Drug carrier

About: Drug carrier is a research topic. Over the lifetime, 18276 publications have been published within this topic receiving 997718 citations. The topic is also known as: drug carriers & drug vehicle.


Papers
More filters
Journal ArticleDOI
TL;DR: Potent antitumor efficacy and reduced side effects of drugs delivered by biocompatible aptNTrs were demonstrated in a mouse xenograft tumor model, and fluorophores on nanotrains and drug fluorescence dequenching upon release allowed intracellular signaling of nanotRains and drugs.
Abstract: Nanotechnology has allowed the construction of various nanostructures for applications, including biomedicine. However, a simple target-specific, economical, and biocompatible drug delivery platform with high maximum tolerated doses is still in demand. Here, we report aptamer-tethered DNA nanotrains (aptNTrs) as carriers for targeted drug transport in cancer therapy. Long aptNTrs were self-assembled from only two short DNA upon initiation by modified aptamers, which worked like locomotives guiding nanotrains toward target cancer cells. Meanwhile, tandem “boxcars” served as carriers with high payload capacity of drugs that were transported to target cells and induced selective cytotoxicity. aptNTrs enhanced maximum tolerated dose in nontarget cells. Potent antitumor efficacy and reduced side effects of drugs delivered by biocompatible aptNTrs were demonstrated in a mouse xenograft tumor model. Moreover, fluorophores on nanotrains and drug fluorescence dequenching upon release allowed intracellular signaling of nanotrains and drugs. These results make aptNTrs a promising targeted drug transport platform for cancer theranostics.

463 citations

Journal ArticleDOI
TL;DR: Sterically stabilized liposomes, containing entrapped doxorubicin, targeted to squamous cell lung carcinoma by means of specific antibodies attached at the liposome surface are capable of reducing tumour burden to a significant extent and eradicating tumour in a significant percentage of mice.

463 citations

Journal ArticleDOI
03 Aug 2009-Small
TL;DR: In this Review, the recent strategic development of drug delivery is discussed with emphasis on polymer-based, especially protein- based, nanomedicine platforms for drug delivery, including protein cages, microspheres, nanoparticles, hydrogels, films, minirods, and minipellets.
Abstract: Protein-based nanomedicine platforms for drug delivery comprise naturally self-assembled protein subunits of the same protein or a combination of proteins making up a complete system. They are ideal for drug-delivery platforms due to their biocompatibility and biodegradability coupled with low toxicity. A variety of proteins have been used and characterized for drug-delivery systems, including the ferritin/apoferritin protein cage, plant-derived viral capsids, the small Heat shock protein (sHsp) cage, albumin, soy and whey protein, collagen, and gelatin. There are many different types and shapes that have been prepared to deliver drug molecules using protein-based platforms, including various protein cages, microspheres, nanoparticles, hydrogels, films, minirods, and minipellets. The protein cage is the most newly developed biomaterial for drug delivery and therapeutic applications. The uniform size, multifunctionality, and biodegradability push it to the frontier of drug delivery. In this Review, the recent strategic development of drug delivery is discussed with emphasis on polymer-based, especially protein-based, nanomedicine platforms for drug delivery. The advantages and disadvantages are also discussed for each type of protein-based drug-delivery system.

462 citations

Journal ArticleDOI
01 Jan 2005-Neurorx
TL;DR: Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration.
Abstract: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50–300 nm generally). They cannot freely diffuse through the blood-brain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyano-acrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

462 citations

Journal ArticleDOI
TL;DR: Results of the study suggest that nanoparticle formulations of selective ER modulators, like tamoxifen, would provide increased therapeutic benefit by delivering the drug in the vicinity of the ER.

462 citations


Network Information
Related Topics (5)
Drug delivery
49.7K papers, 1.8M citations
96% related
Nanoparticle
85.9K papers, 2.6M citations
83% related
In vivo
61.3K papers, 1.9M citations
82% related
Polymer
131.4K papers, 2.6M citations
80% related
Particle size
69.8K papers, 1.7M citations
79% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202366
2022180
2021645
2020815
2019788
2018960